Group financial statement for the first nine months of 2011 - Novozymes A/S

Satisfactory 9 months sales and earnings development with strong free cash flow. Full-year 2011 sales growth expected at ~ 8% in DKK, EBIT growth at 9−11%.

28. Oktober 2011 02:00 ET  | Quelle: Novonesis (Novozymes A/S) Novonesis (Novozymes A/S)